"Gout Suppressants" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that increase uric acid excretion by the kidney (URICOSURIC AGENTS), decrease uric acid production (antihyperuricemics), or alleviate the pain and inflammation of acute attacks of gout.
| Descriptor ID |
D006074
|
| MeSH Number(s) |
D27.505.954.329.337
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Gout Suppressants".
Below are MeSH descriptors whose meaning is more specific than "Gout Suppressants".
This graph shows the total number of publications written about "Gout Suppressants" by people in this website by year, and whether "Gout Suppressants" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Gout Suppressants" by people in Profiles.
-
Baraf HS, Yood RA, Ottery FD, Sundy JS, Becker MA. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014 Dec; 20(8):427-32.
-
Chhabra L, Spodick DH. Colchicine for pericarditis. Am J Health Syst Pharm. 2014 Dec 01; 71(23):2012-3.
-
Baraf HS, Becker MA, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Rehrig CD, Ottery FD, Sundy JS, Yood RA. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013 Sep 26; 15(5):R137.
-
Harrold LR, Mazor KM, Negron A, Ogarek J, Firneno C, Yood RA. Primary care providers' knowledge, beliefs and treatment practices for gout: results of a physician questionnaire. Rheumatology (Oxford). 2013 Sep; 52(9):1623-9.
-
Becker MA, Baraf HS, Yood RA, Dillon A, V?zquez-Mellado J, Ottery FD, Khanna D, Sundy JS. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013 Sep 01; 72(9):1469-74.
-
Harrold LR, Mazor KM, Peterson D, Naz N, Firneno C, Yood RA. Patients' knowledge and beliefs concerning gout and its treatment: a population based study. BMC Musculoskelet Disord. 2012 Sep 21; 13:180.
-
Spodick DH. Colchicine effectively and safely treats acute pericarditis and prevents and treats recurrent pericarditides. Heart. 2012 Jul; 98(14):1035-6.
-
Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, V?zquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW, Hamburger SA, Becker MA. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011 Aug 17; 306(7):711-20.
-
Harrold LR, Mazor KM, Velten S, Ockene IS, Yood RA. Patients and providers view gout differently: a qualitative study. Chronic Illn. 2010 Dec; 6(4):263-71.
-
Harrold LR, Andrade SE, Briesacher B, Raebel MA, Fouayzi H, Yood RA, Ockene IS. The dynamics of chronic gout treatment: medication gaps and return to therapy. Am J Med. 2010 Jan; 123(1):54-9.